Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0188/95 (Tablets/YAMANOUCHI) 04-12-1997
Facebook X Linkedin Email

T 0188/95 (Tablets/YAMANOUCHI) 04-12-1997

European Case Law Identifier
ECLI:EP:BA:1997:T018895.19971204
Date of decision
04 December 1997
Case number
T 0188/95
Petition for review of
-
Application number
86200589.9
IPC class
A61K 31/635
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 631.7 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Tablets comprising trimethoprim and a sulfonamide

Applicant name
YAMANOUCHI EUROPE B.V.
Opponent name
-
Board
3.3.02
Headnote
-
Relevant legal provisions
European Patent Convention Art 56 1973
European Patent Convention R 67 1973
Keywords

Problem invention (no)

Inventive step (yes)

Procedural violation (no)

Catchword
-
Cited decisions
T 0018/81
Citing decisions
-

I. European patent application No. 86 200 589.9 filed on 7. April 1986 and published as EP-A-0 200 252 was refused by the decision of the Examining Division dated 16. September 1994. The decision was based on claims 1 to 12 as originally filed for all designated contracting states other than Austria, with the corrections to claims 1 and 9 requested with the Applicant's letter of 12 June 1990, and claims 1 to 12 for Austria filed on 27 November 1986.

Independent claims 1 and 10 were worded as follows:

"1. Tablets containing trimethoprim or a salt thereof and a sulfonamide or a salt thereof in a ratio between 1:20 and 20:1, the total weight of said ingredients being from 80 to 98% of the total weight of the tablet, characterized in that they comprise an ion exchanger of the artificial resin type.

10. Process for the preparation of tablets as defined in claim 1, characterized in that a mixture is made, comprising trimethoprim or a salt thereof and a sulfonamide or a salt thereof, the mixture is granulated with a suitable liquid, the granulate is mixed with one or more other ingredients and tablets are compressed from the mixture and an ion exchanger of the artificial resin type is added during the preparation of the granulate and/or added to the granulate."

Claims 1 and 10 were followed by dependent claims 2 to 9. and 11 to 13 relating to specific embodiments of the respective independent claims.

II. The stated ground for the refusal was lack of inventive step of all claims. The Examining Division considered GB-A-2 067 900 (document 1) to be the closest state of the art and found that the claimed tablets in the application differed from those disclosed in (1) by the mere fact that crosslinked (insoluble) polyvinylpyrrolidone, used in the known tablets as a strongly swelling disintegrating agent, had been replaced by an ion exchanger of the artificial resin type.

It was already stated in the description of the present application as filed (cf. page 1, paragraph 4) and repeated by the Appellant in his submissions that the use in the prior art of a strongly swelling disintegrating agent was to be considered as disadvantageous insofar as it was responsible to render this kind of tablets slimy and sticky already in contact with a small amount of water in the mouth thereby causing an unwanted bitter aftertaste on administration.

Thus, the technical problem was defined in the impugned decision (see Reasons; point 3) as that of "making tablets based on a high amount of the active ingredients trimethoprim and a sulfonamide which dissolve quickly in water and do not leave a bitter aftertaste."

In the opinion of the Examining Division, the skilled person seeking a solution to this problem in the state of the art would have known from Pharmaceutica Acta Helvetiae, 57, 1982, pp. 131-135 (document 5), that an ion exchanger of the artificial resin type, such as Amberlite IRP 88R , was a particularly suitable disintegrating agent for making certain fast-disintegrating tablets containing more than 80% of a water insoluble ingredient, more specifically phenacetin. He would also have obtained from Drug Development and Industrial Pharmacy, 6, 511-536, 1980, p. 527 (document 6), all the relevant information he needed about the swelling properties of the commonly used disintegrating agents, including Amberlite IRP 88R.

In the light of the above, the Examining Division took the view that it was a matter of routine for the skilled practitioner to solve the technical problem by replacing crosslinked polyvinylpyrrolidone used in (1) as the disintegrating agent with an ion exchanger of the artificial resin type which had already been suggested in (5) for a similar purpose.

III. An appeal against the above decision was filed by the Applicant on 16 November 1994 and oral proceedings took place on 4 December 1997. During presentation of his arguments in support of the appeal both in the written procedure and at the oral proceedings, the Appellant, starting from (1) or GB-A-149 967 (document 2) as the closest state of the art, arrived at a technical problem which was substantially identical with that adopted by the Examining Division.

The Appellant essentially argued that it was solely the contribution of the present inventors to have recognised the bitter aftertaste as a serious drawback of the known tablets resulting from the use of a strongly swelling disintegrating agent in the prior art of (1) and (2). Since the disintegration properties of the known tablets were excellent, the skilled person, faced with the instant technical problem, would have thought of replacing the excipients used in the prior art as the wet binding agents to avoid stickiness, or would have thought of different taste-masking techniques to get rid of the bitter aftertaste, rather than of replacing the disintegrating agent.

Moreover, the question to be answered was not whether the skilled person could have modified in view of the teaching of (5) the known composition of the tablet but whether he would have done so in the expectation of a technical benefit. This question had to be denied since the state of the art was entirely silent about a correlation between the swelling properties of the disintegrating agent and the occurrence of a bitter aftertaste in tablets. The choice of another disintegrating agent having significantly different swelling properties to solve the technical problem was thus far from being obvious.

The Appellant requested that the impugned decision be set aside and a patent be granted on the basis of the two set of claims refused by the Examining Division (see paragraph I above) and the original description with the corrections at line 29 on page 1 and in Example 1 submitted during oral proceedings before the Board of Appeal.

IV. The Appellant further requested the reimbursement of the appeal fee in view of alleged procedural violations and submitted in support of this request essentially the following arguments:

Although the correct technical problem had been introduced by the Appellant already at a very early stage in the proceedings, he felt that it was totally ignored during examination of the present case and was adopted by the Examining Division for the first time in the impugned decision. The Appellant considered this as indicative of the fact that the Examining Division had failed to pay due attention to the arguments and observations provided on his part in support of inventive step during the whole proceedings and, hence, contravened the party's right to be heard (Article 113(1) EPC).

The Appellant contended also that document (6), though supplied by himself in support of his case, was used against him without giving him a sufficient opportunity to make observations and referred in this context to Decision T 18/81.

1. The appeal is admissible.

2. The corrections of errors in the original claims concern deletion of the erroneous insertion "for the preparation of tablets" between "Tablets" and "containing" in line 1 of the precharacterizing portion of claim 1 and rectification of a linguistic error in claim 9. The corrections in the description pertain to the replacement of the wrongly cited unit "m" (metre) in the reference to the prior art of (2) at line 29 on page 1 with the correctly cited unit "micrometer", and to the insertion of the missing unit "g" following the numerical value of 28.8 in Example 1.

All requested corrections are obvious in the sense of Rule 88, 2nd sentence, EPC, and are therefore acceptable.

3. Tablets containing an admixture of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine (trimethoprim) and a sulfonamide as the active ingredients in a proportion of more than 80% of the total weight of the tablet are already known in the state of the art. The high proportion of the said admixture is desirable and necessary to facilitate the preparation of tablets which contain the required high dosage of up to 900 mg of the active ingredients but which are nevertheless, as far as their size and physical properties are concerned, suitable for oral administration without undue discomfort to patients.

Document (2) discloses such tablets comprising from 80 to 98% by weight of an admixture of trimethoprim and a sulfonamide, in which the admixture has a particle size, defined in terms of "weight median diameter", of less than 40 micrometer and which include among other conventional excipients, such as a wet binding agent, a strongly swelling disintegrating agent having a swelling capacity greater than 5 ml/g. The swelling capacity of the disintegrating agent is defined in (2) as the volume (ml) to which 1g of a tablet containing 95% (w/w) of the dry disintegrating agent and 5% (w/w) of polyvinylpyrrolidone will swell when in contact with an excess of water at a temperature of 21 C.

The tabulated test results in the table on page 5 of (2) in connection with the corresponding statements in the specification, in particular at lines 14 to 30 on page 2 and at lines 2 to 6 on page 5 relating to the said test results, provide the skilled reader with the teaching that the use of a disintegrating agent with the indicated strong swelling capacity was regarded in (2) as crucial to produce tablets having a satisfactorily short disintegration time in water between about 1 and 3 minutes, in spite of their high content of the active ingredients which both are highly insoluble in water.

Document (1) which was published later than document (2) contains in the introductory part a reference to document (2) and may be considered as relating to a specific embodiment of the more general technical teaching given in (2). Thus, document (1) discloses in the only example included in the specification a tablet comprising 93% by weight of an admixture of trimethoprim and sulfamethoxazole in combination with 5.5% by weight of crosslinked insoluble polyvinylpyrrolidone (hereinafter referred to under the trade name PolyplasdoneR, see document (5), page 1, paragraph 2.1) as the disintegrating agent and for the remainder certain other conventional excipients such as soluble polyvinylpyrrolidone as a wet binding agent.

It is derivable from the swelling properties listed in (6) for a respectable number of pure tablet disintegrants that PolyplasdoneR reaches its maximum swelling capacity of 112% within a period of time of 9. minutes with a swelling capacity of 39% within the first minute, and appears thus with respect to its swelling properties entirely comparable to certain other strongly swelling disintegrating agents expressly mentioned in (2), for example sodium carboxymethyl starch known under the common name PrimojelR (see (6), page 527, Table 6).

Tablets disclosed in (1) show a disintegration time of less than 1 minute.

4. The tablets disclosed in (1) and (2) exhibit admittedly satisfactory properties, as far as their size, their high proportion of the active ingredients combined with reasonably short disintegration times in water and their other physical properties such as hardness, abrasion and friability are concerned. Notwithstanding this, the Appellant sees a serious drawback of the known tablets in the fact that the strongly swelling disintegrating agent used in the state of the art becomes slimy and sticky already in contact with a small amount of liquid in the mouth. This property of the disintegrating agent was realized by the Appellant to be responsible that the resulting tablets may develop a lingering bitter aftertaste on administration which originates from the inherent bitter taste of trimethoprim and the sulfonamide and is met with some measure of discomfort to patients.

In the light of the closest state of the art, such as illustrated by the documents (1) and (2), the technical problem may thus be seen in providing tablets which meet with regard to their size, their high proportion of the active ingredients trimethoprim and the sulfonamide, their short disintegration time in water and their other physical properties at least the standards achieved in the cited state of the art, but which do not develop a bitter aftertaste on administration.

According to the application it is proposed to solve this technical problem essentially by replacing the strongly swelling disintegrating agent used in the prior art with an ion exchanger of the artificial resin type, typically an Amberlite-type resin, optionally in combination with other excipients.

In view of the content of up to 98% of the active ingredients (cf. Example 18), disintegration times in the range of from less than 15 seconds (cf. Examples 17, 19) to less than 60 seconds maximum, and the good physical properties reported for the tablets produced in accordance with the examples included in the present application and, moreover, in view of the rather low maximum swelling capacity of 57% after 15 minutes with only 17% within the first minute reported in (6) for the disintegrating agent preferably used in the said examples, the Board has no reasonable doubts that the technical problem defined above has in fact plausibly been solved.

5. After examination of the citations uncovered by the search report and those introduced by the Appellant during the proceedings, the Board has reached the conclusion that none of them discloses a tablet including all the technical features stated in claim 1. Since this has never been disputed, there is no need for further detailed substantiation of this matter. Therefore, the subject-matter as set forth in the present claims is deemed to be novel within the meaning of Article 54(1) EPC.

6. The issue in the present case is therefore that of inventive step. From the assessment of this matter, the following points emerge:

6.1. The Appellant also argued at the oral proceedings that it was solely the merit of the present inventors to have recognised for the first time the technical problem actually forming the basis of the present application and this should at least contribute to the acknowledgment of an inventive step in the present case.

It is true that none of the cited documents discloses or otherwise explicitly refers to the drawback of the known tablets resulting from their bitter aftertaste on oral administration. Notwithstanding this, any person taking such a tablet would, in the Board's judgement, normally immediately realize their bitter aftertaste as a discomfort and drawback. Since the overcoming of such a perfectly obvious, directly identifiable drawback and the achievement of an improvement resulting therefrom must be considered as the normal task of the skilled person, the Board cannot share the Appellant's view that a contribution to the inventive step could possibly be seen in the present case already in the perception of the particular technical problem as defined in paragraph 4 above.

6.2. It remains therefore to be examined whether the claimed solution is obvious to a skilled person in view of the prior art.

First of all it should be noted that there is no direct correlation derivable from the state of the art available in the proceedings between the bitter aftertaste of a tablet of any kind and the particular properties of the tablet disintegrant used. Moreover, since the bitter aftertaste of the known tablets has its origin clearly in the extremely bitter taste of both the active ingredients, trimethoprim and the sulfonamide, it was, in the Board's judgement, at the date of priority of the present application not readily to be expected for a skilled person that such bitter aftertaste could successfully be avoided just by replacing the disintegrating agents used in the state of the art which are, according to the Appellant's assertion during oral proceedings, in contrast to the active ingredients entirely tasteless.

Thus, it cannot be considered obvious that the instant technical problem could only be solved by replacing the disintegrating agent. For one thing, various ways of solving the problem posed presented themselves to the person skilled in the art. For example, there was the frequently used and, in the Board's opinion, more obvious possibility of using certain well known taste-masking techniques to get rid of the bitter aftertaste, such as encapsulation or entrapment of the active ingredients, or covering the tablets with a tasteless or good tasting coating, or including certain sweeteners in the tablet mass. The Board concurs also with the Appellant's opinion that another realistic alternative the skilled person could have thought of was the possibility of avoiding stickiness by exchanging certain excipients of the tablets which have inherently water binding and sticky properties such as, for example, the wet granulation binding agents used for the preparation of the tablets disclosed in (1) and (2), rather than by replacing the disintegrating agents.

6.3. From document (5) an ion exchanger of the artificial resin type, more specifically Amberlite IRP 88R, is indeed known as the disintegrating agent for the preparation of certain fast-disintegrating tablets containing phenacetin, which is also sparingly soluble in water, as the active ingredient in a proportion of about 80% by weight. Any indication that this particular disintegrant is to serve to avoid a bitter aftertaste of the tablet is lacking, however. Moreover, it appears also necessary to point to the substantial difference in structure which exists between phenacetin, on the one hand, and trimethoprim and compounds belonging to the class of the sulfonamides, on the other.

What basically distinguishes the disintegrant Amberlite IRP 88R from those used in the cited state of the art as well as from essentially all other disintegrating agents alternatively suggested in (5) for the same purpose as Amberlite IRP 88R, for example PrimojelR, PolyplasdoneR, Ac Di SolR, are its moderate swelling properties reported in (6) and already mentioned in paragraph 4 above.

In this respect it appears worthwhile to note that both the documents (1) and (2) impressively demonstrate the considerable effort that was necessary in the state of the art to obtain tablets containing trimethoprim and a sulfonamide having the desired short disintegration time and adequate physical properties in spite of their high content of the active ingredients. The success achieved in this respect can be clearly attributed in the cited documents to the use of a strongly swelling disintegrating agent. Thus, in the Board's opinion, the skilled person faced with the instant technical problem would have been rather reluctant to jeopardize the progress achieved in the state of the art by using a disintegrant having swelling properties, which are distinctly different from those used in (1) and (2) as has Amberlite IRP 88R.

Moreover, the skilled person would learn on closer inspection of the data provided in Table 4 on page 135 of document (5) that the shortest disintegration time of phenacetin-containing tablets is achieved by using Ac Di SolR as the disintegrating agent followed by Amberlite IRP 88R. However, knowing from the prior art of (1) and (2) the relevance of the strong swelling capacity of the tablet disintegrant to the disintegration time and the other physical properties of a tablet containing trimethoprim and a sulfonamide, he would also scrutinize the swelling properties of the disintegrants listed in (6) to learn that Ac Di SolR ensures not only the shortest disintegration time but at the same time has the highest maximum swelling capacity of 210% in that list, and other disintegration agents mentioned in (5), for example PrimogelR and PolyplasdoneR belong to the class of strongly swelling disintegrating agents as well, in sharp contrast to Amberlite IRP 88R.

In view of the foregoing the Board considers that the skilled person could not expect the problem defined hereinbefore to be solvable in its entirety just by using the particular disintegrating agent chosen in the application. Apart from the fact that the prior art provides absolutely no indication that the bitter aftertaste was in any kind related to the properties of the disintegrating agents used in the known tablets, the skilled person had to entirely ignore the correlation which has been established in the closest state of the art of (1) and (2) between the swelling properties of the disintegrant used and the disintegration time and the physical properties of the resulting tablets, in order to arrive at the solution proposed in the application.

Moreover in the Board's judgment the skilled person could on the basis of the prior art also not expect that the claimed tablets in the application would with respect to their desirably short disintegration time in the range of less than 15 to less than 60 seconds, as already mentioned in paragraph 4 above, compare favourably with those disclosed in the state of the art of (1) and (2).

6.4. In conclusion, the teaching of the application under consideration cannot be considered as obvious within the meaning of Article 56 EPC, whether expressed in accordance with independent claims 1 and 10 or their sub-claims, and consequently involves an inventive step.

7. Following from Rule 67 EPC reimbursement of the appeal fee is due in cases in which the Board of Appeal deems the appeal to be allowable if "such reimbursement is equitable by reason of a substantial procedural violation."

The Board cannot recognise such a substantial procedural violation in the present case. First of all, the impugned decision and preceding proceedings, including the four communications issued pursuant to Article 96(2) and Rule 51(2) and the minutes of the oral proceedings, show that the Examining Division has prepared its negative decision to the Appellant so that he could not have been surprised and his right to be heard has therefore been observed.

As has been admitted by the Appellant himself, the arguments in the decision under appeal are based on a technical problem which has been adapted in order to take into account the arguments provided by the Appellant in his submissions during the proceedings and to which he fully agrees. The decision moreover enables the reader to follow a line of arguments for refusing the application and is essentially based on arguments which had already been communicated to the Appellant before the final decision was made. The Board therefore holds that the Examining Division did not use new arguments in its decision, and that Article 113(1) EPC has been observed.

The Board takes the view that, contrary to what the Appellant appeared to suggest in his submission during oral proceedings, Article 113(1) EPC is not violated by the mere fact that the Examining Division regarded certain arguments and submissions produced by the Applicant as possibly not relevant. Assessment of the relevance of arguments and evidence put forward is a matter for the instance which took the decision and, under Article 97(1) EPC, such a decision concerns the application itself and the invention involved, and not the Applicant's arguments.

8. As far as document (6) is concerned the Board cannot see that the Appellant has found himself in a position corresponding to that which formed the basis of Decision T 18/81 (OJ EPO 1985, 166). First of all, the minutes of the oral proceedings before the Examining Division submitted to the Appellant on 16 September 1994 (see especially the paragraph bridging pages 2 and 3) provide evidence that document (6) has been discussed during the said proceedings and, moreover, that the Examining Division expressed to the Appellant its opinion about the non-relevance of this document to support an inventive step in the present case, so that he had, in the Board's judgement, the opportunity to make his observations.

Moreover, the Appellant himself has filed document (6) with the clear intention to provide information and evidence about the various swelling properties of certain known disintegrants, including the difference in this respect between PolyplasdoneR and Amberlite IRP 88R. As this is virtually the only information which can be derived from (6), the Appellant cannot reasonably argue that the document was used against him in a surprising manner and that he had no opportunity to make observations on the information used. Finally, the decision under appeal cannot be considered to be essentially based on document (6), as it was the case with the documents introduced in the case of T 18/81.

9. In these circumstances, the Board sees no substantial procedural violations in the decision of the first instance, and therefore no valid reason for refunding the fee for appeal under Rule 67 EPC.

Order

ORDER

For these reasons, it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance with the order to grant the patent in the following version:

Claims 1 to 12 for all designated contracting states, Austria excepted;

Claims 1 to 12 for Austria;

both sets of claims as annexed to the decision under appeal;

description pages 2, 3, 5 to 12, as originally filed;

description pages 1 and 4, received during oral proceedings.

3. The request for reimbursement of the appeal fee is refused.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility